Search Results - jeffrey+cohen

4 Results

Sort By:

Epstein-Barr Virus Antibody That Blocks Fusion And Neutralizes Virus Infection of B Cells

Epstein-Barr virus (EBV) is the most common cause of infectious mononucleosis and is associated with nearly 200,000 cancers and 140,000 deaths each year. EBV-associated cancers include Hodgkin's lymphoma, non-Hodgkin's lymphoma, Burkitt B cell lymphoma, and EBV post-transplant lymphoproliferative disease. The latent reservoir for EBV in the body is...

Published: 7/25/2024 | Inventor(s): Wei Bu, Nathan Board, Kennichl Dowdell, Jeffrey Cohen

Keywords(s): ANTIBODY, B, BLOCKS, Cells, DAXXXX, DB4BXX, DB4XXX, DB5XXX, DBXXXX, DC1XXX, DCXXXX, DDXXXX, DXXXXX, EPSTEIN-BARR, Fusion, Infection, Neutralizes, That, virus

Category(s): Collaboration Sought > Collaboration, Application > Diagnostics, Application > Research Materials, Application > Vaccines, Application > Therapeutics, TherapeuticArea > Infectious Disease

Novel Epstein-Barr Virus Vaccines

Epstein-Barr Virus (EBV) is the causative agent of infectious mononucleosis and is associated with certain types of cancers, such as Hodgkin's lymphoma, Burkitt's lymphoma, gastric carcinoma, and nasopharyngeal carcinoma. There are currently no vaccines against EBV on the market and there is only supportive treatment available for EBV infection. The...

Published: 7/25/2024 | Inventor(s): Wei Bu, Gary Nabel, Jeffrey Cohen, Masaru Kanekiyo

Keywords(s): D, DC5BXX, Development, EPSTEIN-BARR, Evelopment, Listed LPM Chang as of 4/15/2015, Nanoparticle-Based, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, vaccines, VCXXXX, virus, VLXXXX, YAXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology, Application > Vaccines

Safer Attenuated Virus Vaccines with Missing or Diminished Latency of Infection

This technology describes recombinant viruses that have weakened ability to establish and/or maintain latency and their use as live vaccines. The viruses have one or more genetic mutations that allow for continued replication but that inhibit latency. The vaccine materials and methods for their construction are exemplified with the virus that causes...

Published: 7/25/2024 | Inventor(s): Lesley Pesnicak, Edward Cox, Jeffrey Cohen

Keywords(s): BUT, chickenpox, DC5BXX, DC5XXX, DCXXXX, DXXXXX, Impaired, Latency, MUTANT, Patent Category - Biotechnology, REPLICATION, UAXXXX, Vaccine, VARICELLA-ZOSTER

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, TherapeuticArea > Rare / Neglected Diseases, Application > Vaccines

A Varicella-Zoster Virus Mutant that is Markedly Impaired for Latent Infection Available for the Development of Shingles Vaccines and Diagnostics

Reactivation of latent Varicella-Zoster virus (VZV) infection is the cause of shingles, which is prominent in adults over the age of 60 and individuals who have compromised immune systems, due to HIV infection, cancer treatment and/or transplant. Shingles is a worldwide health concern that affects approximately 600,000 Americans each year. The incidence...

Published: 7/25/2024 | Inventor(s): Lesley Pesnicak, Jeffrey Cohen

Keywords(s): DA4BXX, DA4XXX, DAXXXX, DC5BXX, DC5XXX, DCXXXX, DXXXXX, imparied latency, Infection, Latent, MUTANT, ORF29 mutant, Varicella Zoster, VARICELLA-ZOSTER, virus

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Diagnostics, Application > Vaccines